Lakewood-Amedex Biotherapeutics, Inc.
LABT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$350.13K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $350,131.00 |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-2.76 |
| Beta | -4.76 |
| Outstanding Shares | 1,419,767 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-2.66
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-1.33
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Lakewood-Amedex Biotherapeutics, Inc.
5 employees
CEO: Kelvin Cooper
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial ...